Die Relevanz einer B-Zell-abhängigen Immunpathologie für die Multiple Sklerose

S. Kuerten; R. Pauly; S. Blaschke; A. Rottlaender; C. C. Kaiser; M. Schroeter; G. R. Fink; K. Addicks

doi:10.1055/s-0029-1245937

Fortschritte der Neurologie · Psychiatrie, Table of Contents

Fortschr Neurol Psychiatr 2011; 79(2): 83-91
DOI: 10.1055/s-0029-1245937

Übersicht

Die Relevanz einer B-Zell-abhängigen Immunpathologie für die Multiple Sklerose

The Significance of a B Cell-Dependent Immunopathology in Multiple SclerosisS. Kuerten¹ , R. Pauly¹ , S. Blaschke¹ , A. Rottlaender¹ , C. C. Kaiser² , M. Schroeter² , G. R. Fink² , K. Addicks¹

¹Anatomie I, Universität zu Köln
²Klinik und Poliklinik für Neurologie, Universitätsklinikum Köln

Abstract

Zusammenfassung

Die Immunpathologie der Multiplen Sklerose (MS) ist bis heute nicht vollständig verstanden. Im Mittelpunkt der vorliegenden Arbeit stehen die B-Lymphozyten, die als Produzenten von Autoantikörpern und durch die Fähigkeit zur Präsentation von Antigenen eine Schlüsselstellung einnehmen können, jedoch bislang in ihrer Bedeutung für die MS unterschätzt wurden. Auch wird die Bildung von ektopen B-Zell-Follikeln im ZNS und deren mögliche Korrelation mit dem Krankheitsverlauf und Schweregrad diskutiert. Nicht zuletzt sollen regulatorische Aspekte einer B-Zell-abhängigen Pathologie erwähnt werden. Ein umfassendes Verständnis der komplexen Immunprozesse der MS kann Therapien hervorbringen, die spezifisch in die Pathogenese eingreifen. Ansatzpunkte einer B-Zell-orientierten Therapie werden im Folgenden erörtert. Insgesamt soll dieser Übersichtsartikel dazu anstoßen, bestehende Paradigmen der Erkrankung zu überdenken und die Rolle der B-Lymphozyten bei der MS zu würdigen.

Abstract

In spite of keen clinical and neuroscientific interest, the aetiology and immunopathology of multiple sclerosis (MS) remain to be elucidated. The present work seeks to give insight into the important, but thus far underestimated contribution of B cells to the disease. Emphasis will be placed on the role of B cells as producers of autoantibodies and as antigen presenting cells. In addition, the development of ectopic B cell follicles in the CNS and their potential correlation with the course of the disease and MS severity will be discussed. Finally, regulatory functions of a B cell-dependent immunopathology should be mentioned. A better understanding of the complex pathomechanisms of MS will allow for therapeutic options that are causative. Potential targets of a B cell-oriented therapy will be delineated in the following review. We hereby aim at triggering a critical re-evaluation of traditional paradigms assigned to MS, appreciating the importance of B cells in the disease.

Schlüsselwörter

Antikörper - Autoimmunität - B-Lymphozyten - EAE - MS

Keywords

antibodies - autoimmunity - B cells - EAE - MS

Full Text

References

Literatur

1 Batoulis H, Addicks K, Kuerten S. Emerging concepts in autoimmune encephalomyelitis beyond the CD 4 /T(H)1 paradigm. Ann Anat. 2010; 192 179-193
2 Lassmann H, Ransohoff R M. The CD 4-Th1 model for multiple sclerosis: a critical re-appraisal. Trends Immunol. 2004; 25 132-137
3 Awad A, Hemmer B, Hartung H P et al. Analyses of cerebrospinal fluid in the diagnosis and monitoring of multiple sclerosis. J Neuroimmunol. 2010; 219 1-7
4 Luque F A, Jaffe S L. Cerebrospinal fluid analysis in multiple sclerosis. Int Rev Neurobiol. 2007; 79 341-56
5 Sospedra M, Martin R. Immunology of multiple sclerosis. Annu Rev Immunol. 2005; 23 683-747
6 Franciotta D, Salvetti M, Lolli F et al. B cells and multiple sclerosis. Lancet Neurol. 2008; 7 852-858
7 Bielekova B, Becker B. Monoclonal antibodies in MS – Mechanisms of action. Neurology. 2010; 74 (Suppl 1) S31-S40
8 Owens G P, Bennett J L, Lassmann H et al. Antibodies produced by clonally expanded plasma cells in multiple sclerosis cerebrospinal fluid. Ann Neurol. 2009; 65 639-649
9 Reindl M, Linington C, Brehm U et al. Antibodies against the myelin oligodendrocyte glycoprotein and the myelin basic protein in multiple sclerosis and other neurological diseases: a comparative study. Brain. 1999; 122 2047-2056
10 Reindl M, Khalil M, Berger T. Antibodies as biological markers for pathophysiological processes in MS. J Neuroimmunol. 2006; 180 50-62
11 Büdingen H C, Harrer M D, Kuenzle von S et al. Clonally expanded plasma cells in the cerebrospinal fluid of MS patients produce myelin-specific antibodies. Eur J Immunol. 2008; 38 2014-2023
12 Büdingen H C, Gulati von M, Kuenzle S et al. Clonally expanded plasma cells in the cerebrospinal fluid of patients with central nervous system autoimmune demyelination produce „oligoclonal bands”. J Neuroimmunol. 2010; 218 134-139
13 Magliozzi R, Howell O, Vora A et al. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain. 2007; 130 1089-1104
14 Keegan M, König F, McClelland R et al. Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange. Lancet. 2005; 366 579-582
15 Hauser S L, Waubant E, Arnold D L et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008; 358 676-688
16 Schröder A, Ellrichmann G, Chehab G et al. Einsatz von Rituximab in der Behandlung neuroimmunologischer Erkrankungen. Nervenarzt. 2009; 80 155-165
17 Buttmann M. Treating multiple sclerosis with monoclonal antibodies: a 2010 update. Expert Rev Neurother. 2010; 10 791-809
18 Rivers T M, Schwentker F F. Encephalomyelitis accompanied by myelin destruction experimentally produced in monkeys. J Exp Med. 1935; 61 689-702
19 Kabat E A, Moore D H, Landow H. An electrophoretic study of the protein components in cerebrospinal fluid and the relationship to the serum proteins. J Clin Invest. 1942; 21 571-577
20 Link H, Baig S, Jiang Y P et al. B cells and antibodies in MS. Res Immunol. 1989; 140 219-226
21 Bernard C C, Rosbo N K. Immunopathological recognition of autoantigens in multiple sclerosis. Acta Neurol. 1991; 13 171-178
22 Menon de K, Piddlesden S J, Bernard C C. Demyelinating antibodies to myelin oligodendrocyte glycoprotein and galactocerebroside induce degradation of myelin basic protein in isolated human myelin. J Neurochem. 1997; 69 214-222
23 Van der Goes A, Kortekaas M, Hoekstra K et al. The role of anti-myelin (auto)-antibodies in the phagocytosis of myelin by macrophages. J Neuroimmunol. 1999; 101 61-67
24 Ponomarenko N A, Durova O M, Vorobiev I I et al. Autoantibodies to myelin basic protein catalyze site-specific degradation of their antigen. Proc Natl Acad Sci U S A. 2006; 103 281-286
25 Karthigasan J, Garvey J S, Ramamurthy G V et al. Immunolocalization of 17 and 21.5 kDa MBP isoforms in compact myelin and radial component. J Neurocytol. 1996; 25 1-7
26 Wucherpfennig K W. Autoimmunity in the central nervous system: mechanisms of antigen presentation and recognition. Clin Immunol Immunopathol. 1994; 72 293-306
27 Yamamoto Y, Yoshikawa H, Nagano S et al. Myelin-associated oligodendrocytic basic protein is essential for normal arrangement of the radial component in central nervous system myelin. Eur J Neurosci. 1998; 11 847-855
28 Lehmann P V, Forsthuber T, Miller A et al. Spreading of T-cell autoimmunity to cryptic determinants of an autoantigen. Nature. 1992; 358 155-157
29 Popot J L, Pham Dinh D, Dautigny A. Major Myelin proteolipid: the 4-alpha-helix topology. J Membr Biol. 1991; 120 233-246
30 Schliess F, Stoffel W. Evolution of the myelin integral membrane proteins of the central nervous system. Biol Chem Hoppe Seyler. 1991; 372 865-874
31 Tumani H, Hartung H P, Hemmer B et al. Cerebrospinal fluid biomarkers in multiple sclerosis. Neurobiol Dis. 2009; 35 117-127
32 Ehling R, Lutterotti A, Wanschitz J et al. Increased frequencies of serum antibodies to neurofilament light in patients with primary chronic progressive multiple sclerosis. Mult Scler. 2004; 10 601-606
33 Silber E, Semra Y K, Gregson N A et al. Patients with progressive multiple sclerosis have elevated antibodies to neurofilament subunit. Neurology. 2002; 58 1372-1381
34 Sadatipour B T, Greer J M, Pender M P. Increased circulating antiganglioside antibodies in primary and secondary progressive multiple sclerosis. Ann Neurol. 1998; 44 980-983
35 Banki K, Colombo E, Sia F et al. Oligodendrocyte-specific expression and autoantigenicity of transaldolase in multiple sclerosis. J Exp Med. 1994; 180 1649-1663
36 Mathey E K, Derfuss T, Storch M K et al. Neurofascin as novel target for antibody mediated axonal injury. J Exp Med. 2007; 204 2363-2372
37 Menge T, Lalive P H, Budingen H C et al. Antibody responses against galactocerebroside are potential stage-specific biomarkers in multiple sclerosis. J Allergy Clin Immunol. 2005; 116 453-459
38 Villar L M, Sadaba M C, Roldan von E et al. Intrathecal synthesis of oligoclonal IgM against myelin lipids predicts an aggressive disease course in MS. J Clin Invest. 2005; 115 187-194
39 Silber E, Semra Y K, Gregson N A et al. Patients with progressive multiple sclerosis have elevated antibodies to neurofilament subunit. Neurology. 2002; 58 1372-1381
40 Eikelenboom M J, Petzold A, Lazeron R H et al. Multiple sclerosis: Neurofilament light chain antibodies are correlated to cerebral atrophy. Neurology. 2003; 60 219-223
41 Sidén A. Isoelectric focusing and crossed immunoelectrofocusing of CSF immunoglobulins in MS. J Neurol. 1979; 221 39-51
42 Link H, Huang Y M. Oligoclonal bands in multiple sclerosis cerebrospinal fluid: an update on methodology and clinical usefulness. J Neuroimmunol. 2007; 180 17-28
43 Vaheri A, Keski-Oja J, Salonen E M et al. Cerebrospinal fluid IgG bands and virus-specific IgG, IgM, and IgA antibodies in herpes simplex virus encephalitis. J Neuroimmunol. 1982; 3 247-261
44 Stanek G. Laboratory diagnosis and seroepidemiology of Lyme borreliosis. Infection. 1991; 19 263-267
45 Ceroni M, Camana C, Franciotta D M et al. Specific activation of B-cell clones within the central nervous system in course of herpes simplex encephalitis. Boll Soc Ital Biol Sper. 1990; 66 1223-1230
46 Shen X, Tan Y. Detection of oligoclonal immunoglobulins in the cerebrospinal fluid by immunofixation electrophoresis. Clin Chem Lab Med. 2001; 39 1209-1210
47 Dornmair K, Meinl E, Hohlfeld R. Novel approaches for identifying target antigens of autoreactive human B and T cells. Semin Immunopathol. 2009; 31 467-477
48 Lucchinetti C, Brück W, Parisi J et al. Heterogeneity of multiple sclerosis lesions: implications for the pathogenesis of demyelination. Ann Neurol. 2000; 47 707-717
49 Qin Y, Duquette P, Zhang Y et al. Intrathecal B-cell clonal expansion, an early sign of humoral immunity, in the cerebrospinal fluid of patients with clinically isolated syndrome suggestive of multiple sclerosis. Lab Invest. 2003; 83 1081-1088
50 Rock K L, Benacerraf B, Abbas A K. Antigen presentation by hapten-specific B lymphocytes. I. Role of surface immunoglobulin receptors. J Exp Med. 1984; 160 1102-1113
51 Constant S L. B lymphocytes as antigen-presenting cells for CD 4þ T cell priming in vivo. J Immunol. 1999; 162 5695-5703
52 Greter M, Heppner F L, Lemos M P et al. Dendritic cells permit immune invasion of the CNS in animal model of multiple sclerosis. Nat Med. 2005; 11 328-334
53 Racke M. The role of B cells in multiple sclerosis: rationale for B-cell-targeted therapies. Curr Opin Neurol. 2008; 21 (Suppl 1) S9-S18
54 Harp C T, Lovett-Racke A E, Racke M K et al. Impact of myelin-specific antigen presenting B cells on T cell activation in multiple sclerosis. Clin Immunol. 2008; 128 382-391
55 Serafini B, Rosicarelli B, Magliozzi R et al. Detection of ectopic B-cell follicles with germinal centers in meninges of patients with secondary progressive multiple sclerosis. Brain Pathol. 2004; 14 164-174
56 Aloisi F, Pujol-Borrell R. Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol. 2006; 6 205-217
57 Kaiser C C, Shukla D K, Stebbins G T et al. A pilot test of pioglitazone as an add-on in patients with relapsing remitting multiple sclerosis. J Neuroimmunol. 2009; 211 124-130
58 Serafini B, Severa M, Columba-Cabezas S et al. Epstein-Barr virus latent i nfection and BAFF expression in B cells in the multiple sclerosis brain: implications for viral persistence and intrathecal B-cell activation. J Neuropathol Exp Neurol. 2010; 69 677-693
59 Bø L, Vedeler C A, Nyland H et al. Intracortical multiple sclerosis lesions are not associated with increased lymphocyte infiltration. Mult Scler. 2003; 9 323-331
60 Willis S N, Stadelmann C, Rodig S J et al. Epstein-Barr virus infection is not a characteristic feature of multiple sclerosis brain. Brain. 2009; 132 3318-3328
61 Sargsyan S A, Shearer A J, Ritchie A M et al. Absence of Epstein-Barr virus in the brain and CSF of patients with multiple sclerosis. Neurology. 2010; 74 1127-1135
62 Fillatreau S, Sweenie C H, McGeachy M J et al. B cells regulate autoimmunity by provision of IL-10. Nat Immunol. 2002; 3 944-950
63 Matsushita T, Yanaba K, Bouaziz J D et al. Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progression. J Clin Invest. 2008; 118 3420-3430
64 Warrington A E, Asakura K, Bieber A J et al. Human monoclonal antibodies reactive to oligodendrocytes promote remyelination in a model of multiple sclerosis. Proc Natl Acad Sci USA. 2000; 97 6820-6825
65 Gold R, Linington C, Lassmann H. Understanding pathogenesis and therapy of multiple sclerosis via animal models: 70 years of merits and culprits in experimental autoimmune encephalomyelitis research. Brain. 2006; 129 1953-1971
66 Goverman J, Brabb T. Rodent models of experimental allergic encephalomyelitis applied to the study of multiple sclerosis. Lab Anim Sci. 1996; 46 482-492
67 Kuerten S, Angelov D N. Comparing the CNS morphology and immunobiology of different EAE models in C 57BL/ 6 mice – a step towards understanding the complexity of multiple sclerosis. Ann Anat. 2008; 190 1-15
68 Steinmann L, Zamvil S. Virtues and pitfalls of EAE for the development of therapies for multiple sclerosis. Trends in Immunol. 2005; 26 565-571
69 Steinman L, Zamvil S S. How to successfully apply animal studies in experimental allergic encephalomyelitis to research on multiple sclerosis. Ann Neurol. 2006; 60 12-21
70 Yip H C, Karulin A Y, Tary-Lehmann M et al. Adjuvant-guided type-1 and type-2 immunity: infectious/noninfectious dichotomy defines the class of response. J Immunol. 1999; 162 3942-3949
71 Sriram S, Steiner I. Experimental allergic encephalomyelitis: a misleading model of multiple sclerosis. Ann Neurol. 2005; 58 939-945
72 Stefferl A, Storch M K, Linington C et al. Disease progression in chronic relapsing experimental allergic encephalomyelitis is associated with reduced inflammation-driven production of corticosterone. Endocrinology. 2001; 142 3616-3612
73 Genain C P, Nguyen M H, Letvin N L et al. Antibody facilitation of multiple sclerosis-like lesions in a nonhuman primate. J Clin Invest. 1995; 96 2966-2974
74 't Hart B A, Massacesi L. Clinical, pathological, and immunologic aspects of the multiple sclerosis model in common marmosets (Callithrix jacchus). J Neuropathol Exp Neurol. 2009; 68 341-355
75 Hjelmstrom P, Juedes A E, Fjell J et al. B-cell-deficient mice develop experimental allergic encephalomyelitis with demyelination after myelin oligodendrocyte glycoprotein sensitization. J Immunol. 1998; 161 4480-4483
76 Oliver A R, Lyon G M, Ruddle N H. Rat and human myelin oligodendrocyte glycoproteins induce experimental autoimmune encephalomyelitis by different mechanisms in C 57BL/ 6 mice. J Immunol. 2003; 171 462-468
77 Kuerten S, Lichtenegger F S, Faas S et al. MBP-PLP fusion protein-induced EAE in C 57BL/ 6 mice. J Neuroimmunol. 2006; 177 99-111
78 Kuerten S, Javeri S, Tary-Lehmann M et al. Fundamental differences in the CNS lesion development and composition in MP 4- and MOG:35 – 55-induced EAE. Clin Immunol. 2008; 129 256-267
79 Elliott E A, McFarland H I, Nye S H et al. Treatment of experimental encephalomyelitis with a novel chimeric fusion protein of myelin basic protein and proteolipid protein. J Clin Invest. 1996; 98 1602-1612
80 Pöllinger B, Krishnamoorthy G, Berer K et al. Spontaneous relapsing-remitting EAE in the SJL/J mouse: MOG-reactive transgenic T cells recruit endogenous MOG-specific B cells. J Exp Med. 2009; 206 1303-1316
81 Genc K, Dona D L, Reder A T. Increased CD 80(+) B cells in active multiple sclerosis and reversal by interferon beta-1b therapy. J Clin Invest. 1997; 99 2664-2671
82 Kim H J, Ifergan I, Antel J P et al. Type 2 monocyte and microglia differentiation mediated by glatiramer acetate therapy in patients with multiple sclerosis. J Immunol. 2004; 172 7144-7153
83 Kala M, Rhodes S N, Piao W H et al. B cells from glatiramer acetate-treated mice suppress experimental autoimmune encephalomyelitis. Exp Neurol. 2010; 221 136-145
84 Begum-Haque S, Sharma A, Christy M et al. Increased expression of B-cell associated regulatory cytokines by glatiramer acetate in mice with experimental autoimmune encephalomyelitis. J Neuroimmunol. 2010; 219 47-53
85 Krumbholz M, Faber H, Steinmeyer F et al. Interferon-beta increases BAFF levels in multiple sclerosis: implications for B cell autoimmunity. Brain. 2008; 131 1455-1463
86 Steinman L. Blocking adhesion molecules as therapy for multiple sclerosis: natalizumab. Nat Rev Drug Discov. 2005; 4 510-518
87 Rudick R A, Sandrock A. Natalizumab. alpha 4-integrin antagonist selective adhesion molecule inhibitors for MS. Expert Rev Neurother. 2004; 4 571-580
88 Krumbholz M, Meinl I, Kümpfel T et al. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology. 2008; 71 1350-1354
89 Weissert R. Progressive multifocal leukoencephalopathy. J Neuroimmunol. 2010; [Epub ahead of print]
90 Meinl E, Krumbholz M, Hohlfeld R. B linage cells in the inflammatory central nervous system environment: migration, maintenance, local antibody production and therapeutic modulation. Ann Neurol. 2006; 59 880-892
91 Menge T, Büdingen H C, Dalakas M C et al. B-Zell-gerichtete Multiple-Sklerose-Therapie: Aktueller Stand. Nervenarzt. 2009; 80 190-198
92 Cross A H, Stark J L, Lauber J et al. Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patients. J Neuroimmunol. 2006; 180 63-70
93 Nückel H, Frey U H, Röth A et al. Alemtuzumab induces enhanced apoptosis in vitro in B-cells from patients with chronic lymphocytic leukemia by antibody-dependent cellular cytotoxicity. Eur J Pharmacol. 2005; 514 217-224
94 Hawker K. B-cell-targeted treatment for multiple sclerosis: mechanism of action and clinical data. Curr Opin Neurol. 2008; 21 (Suppl 1) S19-S25
95 Monson N. The natural history of B cells. Curr Opin Neurol. 2008; 21 (Suppl 1) S3-S8
96 Chan A, Weilbach F X, Toyka K V et al. Mitoxantrone induces cell death in peripheral blood leucocytes of multiple sclerosis patients. Clin Exp Immunol. 2005; 139 152-158

Dr. Stefanie Kuerten

Anatomie I, Universität zu Köln

Joseph-Stelzmann-Str. 9

50931 Köln

Email: stefanie.kuerten@uk-koeln.de